157 related articles for article (PubMed ID: 33840559)
21. Small Lymph Node Metastasis Detected by 68Ga-Prostate-Specific Membrane Antigen But Not 18F-Fluciclovine PET/CT in Low-Prostate-Specific Antigen Biochemical Recurrence of Prostate Cancer.
Chaussé G; Abikhzer G; Probst S
Clin Nucl Med; 2018 Apr; 43(4):250-251. PubMed ID: 29465489
[TBL] [Abstract][Full Text] [Related]
22. Prospective comparison of whole-body MRI and
Sawicki LM; Kirchner J; Buddensieck C; Antke C; Ullrich T; Schimmöller L; Boos J; Schleich C; Schaarschmidt BM; Buchbender C; Heusch P; Rabenalt R; Albers P; Antoch G; Müller HW; Hautzel H
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1542-1550. PubMed ID: 30879122
[TBL] [Abstract][Full Text] [Related]
23.
Calais J; Czernin J; Cao M; Kishan AU; Hegde JV; Shaverdian N; Sandler K; Chu FI; King CR; Steinberg ML; Rauscher I; Schmidt-Hegemann NS; Poeppel T; Hetkamp P; Ceci F; Herrmann K; Fendler WP; Eiber M; Nickols NG
J Nucl Med; 2018 Feb; 59(2):230-237. PubMed ID: 29123013
[TBL] [Abstract][Full Text] [Related]
24. PSMA PET/CT vs. CT alone in newly diagnosed biochemical recurrence of prostate cancer after radical prostatectomy: Comparison of detection rates and therapeutic implications.
Morawitz J; Kirchner J; Lakes J; Bruckmann NM; Mamlins E; Hiester A; Aissa J; Loberg C; Schimmöller L; Arsov C; Antke C; Albers P; Antoch G; Sawicki LM
Eur J Radiol; 2021 Mar; 136():109556. PubMed ID: 33485127
[TBL] [Abstract][Full Text] [Related]
25. The Clinical Utility of
Nakamoto R; Harrison C; Song H; Guja KE; Hatami N; Nguyen J; Moradi F; Franc BL; Aparici CM; Davidzon G; Iagaru A
Mol Imaging Biol; 2021 Aug; 23(4):614-623. PubMed ID: 33469884
[TBL] [Abstract][Full Text] [Related]
26. Regional Lymph Node Metastasis on Prostate Specific Membrane Antigen Positron Emission Tomography Correlates with Decreased Biochemical Recurrence-Free and Therapy-Free Survival after Radical Prostatectomy: A Retrospective Single-Center Single-Arm Observational Study.
Amiel T; Würnschimmel C; Heck M; Horn T; Nguyen N; Budäus L; Knipper S; Wenzel M; Rauscher I; Eiber M; Wang H; Maurer T
J Urol; 2021 Jun; 205(6):1663-1670. PubMed ID: 33535796
[TBL] [Abstract][Full Text] [Related]
27.
Eiber M; Kroenke M; Wurzer A; Ulbrich L; Jooß L; Maurer T; Horn T; Schiller K; Langbein T; Buschner G; Wester HJ; Weber W
J Nucl Med; 2020 May; 61(5):696-701. PubMed ID: 31836682
[No Abstract] [Full Text] [Related]
28. Comparison Between
Cantiello F; Crocerossa F; Russo GI; Gangemi V; Ferro M; Vartolomei MD; Lucarelli G; Mirabelli M; Scafuro C; Ucciero G; De Cobelli O; Morgia G; Damiano R; Cascini GL
Clin Genitourin Cancer; 2018 Oct; 16(5):385-391. PubMed ID: 29937067
[TBL] [Abstract][Full Text] [Related]
29. Prostate Cancer Imaging with 18F-Fluciclovine.
Savir-Baruch B; Schuster DM
PET Clin; 2022 Oct; 17(4):607-620. PubMed ID: 36229104
[TBL] [Abstract][Full Text] [Related]
30.
Uprimny C; Kroiss AS; Decristoforo C; Fritz J; von Guggenberg E; Kendler D; Scarpa L; di Santo G; Roig LG; Maffey-Steffan J; Horninger W; Virgolini IJ
Eur J Nucl Med Mol Imaging; 2017 Jun; 44(6):941-949. PubMed ID: 28138747
[TBL] [Abstract][Full Text] [Related]
31. [
Alemozaffar M; Akintayo AA; Abiodun-Ojo OA; Patil D; Saeed F; Huang Y; Osunkoya AO; Goodman MM; Sanda M; Schuster DM
J Urol; 2020 Oct; 204(4):734-740. PubMed ID: 32347780
[TBL] [Abstract][Full Text] [Related]
32. Correlation between
Saarinen I; Jambor I; Kim M; Kuisma A; Kemppainen J; Merisaari H; Eskola O; Koskenniemi AR; Perez IM; Boström P; Taimen P; Minn H
EJNMMI Res; 2019 May; 9(1):50. PubMed ID: 31152256
[TBL] [Abstract][Full Text] [Related]
33.
Farolfi A; Ceci F; Castellucci P; Graziani T; Siepe G; Lambertini A; Schiavina R; Lodi F; Morganti AG; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):11-19. PubMed ID: 29905907
[TBL] [Abstract][Full Text] [Related]
34. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of
Fossati N; Scarcella S; Gandaglia G; Suardi N; Robesti D; Boeri L; Karnes RJ; Heidenreich A; Pfister D; Kretschmer A; Buchner A; Stief C; Battaglia A; Joniau S; Van Poppel H; Osmonov D; Juenemann KP; Shariat S; Hiester A; Nini A; Albers P; Tilki D; Graefen M; Gill IS; Mottrie A; Galosi AB; Montorsi F; Briganti A
J Urol; 2020 Aug; 204(2):296-302. PubMed ID: 32068488
[TBL] [Abstract][Full Text] [Related]
35.
Ceci F; Castellucci P; Graziani T; Farolfi A; Fonti C; Lodi F; Fanti S
Eur J Nucl Med Mol Imaging; 2019 Jan; 46(1):31-39. PubMed ID: 30350010
[TBL] [Abstract][Full Text] [Related]
36. High negative predictive value of 68Ga PSMA PET-CT for local lymph node metastases in high risk primary prostate cancer with histopathological correlation.
Rahman LA; Rutagengwa D; Lin P; Lin M; Yap J; Lai K; Mancuso P; Rathore P; Haghighi K; Gassner P; Wong LH; Lalak N
Cancer Imaging; 2019 Dec; 19(1):86. PubMed ID: 31829288
[TBL] [Abstract][Full Text] [Related]
37. Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
Timm B; Farag M; Liodakis P; Angus D; Lim Joon D; Bolton D
BJU Int; 2021 May; 127 Suppl 1():23-29. PubMed ID: 33973332
[TBL] [Abstract][Full Text] [Related]
38. Is There Any Role for 18F-Fluciclovine PET/CT in the Presence of Undetectable PSA in Prostate Cancer Patients After Definitive Treatment?
Teyateeti A; Teyateeti A; Macapinlac HA; Lu Y
Clin Nucl Med; 2020 Sep; 45(9):672-678. PubMed ID: 32604105
[TBL] [Abstract][Full Text] [Related]
39. Outcomes of Primary Lymph Node Staging of Intermediate and High Risk Prostate Cancer with
Yaxley JW; Raveenthiran S; Nouhaud FX; Samartunga H; Yaxley AJ; Coughlin G; Delahunt B; Egevad L; McEwan L; Wong D
J Urol; 2019 Apr; 201(4):815-820. PubMed ID: 30672842
[TBL] [Abstract][Full Text] [Related]
40.
Vinsensia M; Chyoke PL; Hadaschik B; Holland-Letz T; Moltz J; Kopka K; Rauscher I; Mier W; Schwaiger M; Haberkorn U; Mauer T; Kratochwil C; Eiber M; Giesel FL
J Nucl Med; 2017 Dec; 58(12):1949-1955. PubMed ID: 28637799
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
